

GAU 1614

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

05/14/98
 1c588 U.S. PTO

Applicant: Merton Bernfield and Ofer Reizes

Serial No.: 08/965,356

Group Art Unit: Not Yet Assigned

Filed: November 6, 1997

Examiner: Not Yet Assigned

For: METHODS AND REAGENTS FOR REGULATING OBESITY

Assistant Commissioner for Patents
 Washington, D.C. 20231

MAY 15 1998

#4
5/19/98

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. § 1.56 and 37 C.F.R. § 1.97, applicants submit an Information Disclosure Statement, including six pages of Form 1449 and copies of the documents cited therein.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any additional fees to Deposit Account No. 01-2507.

United States Patents

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
3,625,214	12-07-1971	Higuchi	128/260
4,244,946	01-13-1981	Rivier, et al.	424/177

4,305,872	12-15-1981	Johnston, et al.	260/112.5R
4,316,891	02-23-1982	Guillemin, et al.	424/177
4,629,784	12-16-1986	Stammer	530/328
4,789,734	12-06-1988	Pierschbacher	530/395
4,792,525	12-20-1988	Ruoslahti, et al.	435/240.243
4,906,474	03-06-1990	Langer, et al.	424/428
4,925,673	05-15-1990	Steiner, et al.	424/455
5,486,599	01-23-1996	Saunders, et al.	530/395

Foreign Patent Application and Documents

<u>Number</u>	<u>Publication Date</u>	<u>Patentee/Applicant</u>	<u>Country/Region</u>
WO 93/01286 A2	01-21-1993	Massachusetts Institute of Technology	PCT
WO 95/00633 A2	01-05-1995	Childrens Medical Center	PCT
WO 95/34316 A1	12-21-1995	Jalkanen, et al.	PCT
WO 97/47316 A1	12-18-1997	Millennium Pharmaceuticals, Inc.	PCT

Publications

AGRAWAL, et al., "Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus," *Proc. Natl. Acad. Sci. USA* 85(19):7079-7083 (1988).

ASKEW, et al., "Molecular Recognition with Convergent Functional Groups. 6. Synthetic and Structural Studies with a Model Receptor for Nucleic Acid Components," *J. Am. Chem. Soc.* 111(3):1082-1090 (1989).

BERNFIELD, et al., "Biology of the Syndecans: A Family of Transmembrane Heparan Sulfate Proteoglycans," in *Annu. Rev. Cell Biol.*, (Palade, et al., eds.) 8:365-393 (Annual Reviews Inc., Palo Alto, CA, 1992).

CLACKSON, et al., "Making antibody fragments using phage display libraries," *Nature* 352(6336):624-688 (1991).

COLDITZ, "Economic costs of obesity," *Am. J. Clin. Nutr.* 55(2):503S-507S (1992).

DAUGHERTY, et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins," *Nucl. Acids Res.* 19(9):2471-2476 (1991).

DAVID, et al., "Molecular Cloning of a Phosphatidylinositol-anchored Membrane Heparan Sulfate Proteoglycan from Human Lung Fibroblasts," *J. Cell Biol.* 111(6):3165-3176 (1990).

DAVID, "Integral membrane heparan sulfate proteoglycans," *FASEB J.* 7(11):1023-1030 (1993).

ELENIUS, et al., "Induced Expression of Syndecan in Healing Wounds," *J. Cell Biol.* 114(3):585-595 (1991).

ELLINGTON, et al., "Selection *in vitro* of single-stranded DNA molecules that fold into specific ligand-binding structures," *Nature* 355(6363):850-852 (1992).

EZZELL, "Fat Times for Obesity Research: Tons of New Information, but How Does It All Fit Together," *J. NIH Res.* 7:39-43 (1995).

FLIER, "Commentary - Leptin expression and action: New experimental paradigms," *Proc. Natl. Acad. Sci. USA* 94(9):4242-4245 (1997).

GREENWAY, "Surgery for Obesity," *Endo. Metab. Clin. N. Amer.* 25(4):1005-1027 (1996).

GREGORIADIS, "Liposomes," Chapter 14, *Drug Carriers in Biology and Medicine* pp. 287-341 (Academic Press, 1979).

GUAN, et al., "Fibronectin/integrin interaction induces tyrosine phosphorylation of a 120-kDa protein," *Cell Reg.* 2(11):951-964 (1991).

GURA, "Obesity Sheds Its Secrets," *Science* 275:752-753 (1997).

HARADA, et al., "Monoclonal antibody G6K12 specific for membrane-associated differentiation marker of human stratified squamous epithelia and squamous cell carcinoma," *J. Oral Pathol. Med.* (Denmark), 22(f):145-152 (1993).

HAYASHI, et al., "Immunocytochemistry of Cell Surface Heparan Sulfate Proteoglycan in Mouse Tissues. A Light and Electron Microscopic Study," *J. Histochem. Cytochem.* 35(10):1079-1088 (1987).

HIGASHIYAMA, et al., "Heparin-binding EGF-like Growth Factor Stimulation of Smooth Muscle Cell Migration: Dependence on Interactions with Cell Surface Heparan Sulfate," *J. Cell Bio.* 122(4):933-940 (1993).

HUSZAR, et al., "Targeted Disruption of the Melanocortin-4 Receptor Results in Obesity in Mice," *Cell* 88(1):131-141 (1997).

INAI, et al., "Immunohistochemical detection of an enamel protein-related epitope in rat bone at an early stage of osteogenesis," *Histochemistry* (German), 99(5):335-362 (1993).

ITAKURA, et al., "Synthesis and Use of Synthetic Oligonucleotides," *Ann. Rev. Biochem.* 53:323-356 (1984).

JOYNER, et al., "Production of a mutation in mouse *En-2* gene by homologous recombination in embryonic stem cells," *Nature* 338(6211):153-156 (1989).

KABAT, et al., *Sequences of Proteins of Immunological Interest*, 4th Ed. (U.S. Dept. Health and Human Services, Bethesda, MD, 1987)

LEE, et al., "Change in Body Weight and Longevity," *JAMA* 268(15):2045-2049 (1992).

LEWIS, et al., "Automated site-directed drug design: the concept of spacer skeletons for primary structure generation," *Proc. R. Soc. Lond.* 236:125-140 and 141-162 (1989).

LONG, et al., "Weight Loss in Severely Obese Subjects Prevents the Progression of Impaired Glucose Tolerance to Type II Diabetes," *Diabetes Care* 17(5):372-375 (1994).

McKINALY, et al., "Rational Design of Antiviral Agents," *Annu. Rev. Pharmacol. Toxicol.* 29:111-122 (1989).

MERRIFIELD, "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide," *J. Am. Chem. Soc.* 85:2149-2154 (1964).

MORTIMER, et al., "Use of Gene-Manipulated Models To Study The Physiology Of Lipid Transport," *Clinical and Experimental Pharmacology and Physiology* 24(3/4):281-285 (1997).

MULDER, et al., "Characterization of Two Human Monoclonal Antibodies Reactive with HLA-B12 and HLA-B60, Respectively, Raised by *in vitro* Secondary Immunization of Peripheral Blood Lymphocytes," *Hum. Immunol.* 36(3):186-192 (1993).

NARANG, et al., "Chemical Synthesis of Deoxyoligonucleotides by the Modified Triester Method," *Methods Enzymol.* 65:610-620 (1980).

NATIONAL TASK FORCE ON OBESITY, "Long-term Pharmacotherapy in the Management of Obesity," *JAMA* 276(23):1907-1915 (1996).

NIH Conference, "Gastrointestinal Surgery for Severe Obesity," *Ann Intern Med.* 115(12):956-961 (1991).

NIH Technology Assessment Conference Panel, "Methods for Voluntary Weight Loss and Control," *Ann. Intern. Med.* 119(7):764-770 (1993).

OFFENSPERGER, et al., "*In Vivo* inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides," *EMBO J.* 12(3):1257-1262 (1993).

ORSON, et al., "Oligonucleotide inhibition of IL2R α mRNA transcription by promoter region collinear triplex formation in lymphocytes," *Nucleic Acids Res.* 19(12):3435-3441 (1991).

PAULSON, et al., "Glycosyltransferases," *J. Biol. Chem.* 264(30):17615-17618 (1989).

PERRY, et al., QSAR: Quantitative Structure-Activity Relationships in Drug Design (Fauchère, ed.), pp. 189-193 (Alan R. Liss, inc. 1989).

POTTER, et al., "Enhancer-dependent expression of human κ immunoglobulin genes introduced into mouse pre-B lymphocytes by electroporation," *Proc. Natl. Acad. Sci. USA* 81(22):7161-7165 (1984).

RAPRAEGER, "The coordinated regulation of heparan sulfate, syndecans and cell behavior," *Curr. Opin. Cell Biol.* 5(5):844-853 (1993).

RAPRAEGER, et al., "Requirement of Heparan Sulfate for bFGF-Mediated Fibroblast Growth and Myoblast Differentiation," *Science* 252:1705-1708 (1991).

RIPKA, "Computers Picture the Perfect Drug," *New Scientist* 1617:54-57 (1988).

ROUVINEN, et al., "Computer-Aided Drug Design," *Acta Pharmaceutica Fennica* 97:159-166 (1988).

RUOSLAHTI, et al., "Proteoglycans as Modulators of Growth Factor Activities," *Cell* 64(5):867-869 (1991).

SARIN, et al., "Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates," *Proc. Natl. Acad. Sci. USA* 85(20):7448-7794 (1989).

SHAW, et al., "Modified deoxyoligonucleotides stable to exonuclease degradation in serum," *Nucleic Acids Res.* 19(4):747-750 (1991).

SOUTHERN, et al., "Transformation of Mammalian Cells to Antibiotic Resistance with a Bacterial Gene Under Control of the SV40 Early Region Promoter," *J. Mol. Appl. Gen.* 1(4):327-341 (1982).

STÄUBER, et al., "Rapid generation of monoclonal antibody-secreting hybridomas against African horse sickness virus by *in vitro* immunization and the fusion/cloning technique," *J. Immunol. Methods* (Netherlands), 161(2):157-168 (1993).

VENKATESWARAN, et al., "Production of Anti-Fibroblast Growth Factor Receptor Monoclonal Antibodies by *In Vitro* Immunization," *Hybridoma* 11(6):729-739 (1992).

WOLF, et al., "The Cost of Obesity," *Pharmacoeconomics* 5(Supp. 1):34-37 (1994).

WOODS, et al., "A Synthetic Peptide from the COOH-Terminal Heparin-binding Domain of Fibronectin Promotes Focal Adhesion Formation," *Molec. Biol. Cell* 4(6):605-613 (1993).

YAYON, et al., "Cell Surface, Heparin-like Molecules Are Required for Binding of Basic Fibroblast Growth Factor to Its High Affinity Receptor," *Cell* 64(4):841-848 (1991).


ZIMMER, et al., "Production of chimaeric mice containing embryonic stem (ES) cells carrying a homoeobox Hox 1.1 allele mutated by homologous recombination," *Nature* 338(6211):150-153 (1989).

Remarks

While this statement is believed to include all of the material presently known to applicants, it should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, applicants invite the Examiner to make an independent evaluation of the cited art to determine its materiality and relevance to the subject matter of the present application. Applicants are of the opinion that their

claimspatentably distinguish over the prior art referred to herein, either alone or in combination.

Respectfully submitted,


Patrea L. Pabst
Reg. No. 31,284


Date: May 11, 1998

ARNALL GOLDEN & GREGORY, LLP
2800 One Atlantic Center
1201 West Peachtree Street
Atlanta, Georgia 30309-3450
(404) 873-8794
(404) 873-8795 (fax)

Certificate of Mailing under 37 CFR § 1.8(a)

I hereby certify that this paper, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: May 11, 1998


Teresa R. Spratt